$13.92
-0.64%SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Chief Business & Legal Affairs Officer, Secretary and General Counsel
Chief Executive Officer & Director
Compensation
$1,293,959
Chief Financial Officer
Compensation
$743,456
Director of FP&A and Investor Relations
Executive Chairman
Compensation
$90,000
President of Commercial Operations
Compensation
$884,763
Senior Vice President of Clinical & Regulatory Affairs
Senior Vice President of Engineering & Chief Technology Officer
Senior Vice President of Product, Marketing & Business Development
Vice President of People & Culture
During the last 12 months, insiders have sold $3.19M worth of SIBN shares, with no buying activity reported.
0
0.00
17.4K
245.44K
-245K
-$245K
0
0.00
81.3K
1.63M
-1.6M
-$1.63M
0
0.00
70.4K
1.31M
-1.3M
-$1.31M
0
0.00
0
0.00
+0
+$0
No buying activity
Dunn Jeffrey W
Director
$1.88M
Maheshwari Anshul
Officer: Chief Financial Officer
$470K
Pisetsky Michael A.
Officer: Svp, Ops & Adm/Chief Legal Ofr
$429K
Francis Laura
Director, Officer: Chief Executive Officer
$150K
Davis Timothy E Jr
Director
$104K
Strong bearish signal with $3.19M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SIBN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 21, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 29, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | April 21, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | April 22, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 26, 2021 | April 26, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 22, 2020 | April 22, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 13, 2019 | 2019 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.